Douglas L. Jennings

Douglas L. Jennings

Auto-generated profile, based on publicly available information

Douglas L. Jennings

Thomas J. Long School of Pharmacy University of the Pacific Sacramento California USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
DSDavid M. Salerno
David M. Salerno
DJDouglas L. Jennings
Douglas L. Jennings
NLNicholas W. Lange
Nicholas W. Lange
DKDanielle (Bley) Kovac
Danielle (Bley) Kovac
TSTara Shertel
Tara Shertel
MPMarcus R. Pereira
Marcus R. Pereira
Nirmatrelvir/ritonavir (NR) use has not yet been described in solid organ transplant recipients (SOTRs) with mild COVID‐19. The objective was to evaluate outcomes among SOTR and describe the drug–drug interaction of NR. This is an IRB‐approved, retrospective study of all adult SOTR on a calcineurin inhibitor (CNI) or mammalian target of rapamycin inhibitor who were prescribed NR between December 28, 2021 and January 6, 2022. A total of 25 adult SOTR were included (n = 21 tacrolimus, n = 4 cyclosporine, n = 3 everolimus, n = 1 sirolimus). All patients were instructed to follow the following standardized protocol during treatment with 5 days of NR: hold tacrolimus or mTOR inhibitor or reduce cyclosporine dose to 20% of baseline daily dose. Four patients (16%) were hospitalized by day 30; one for infectious diarrhea and three for symptoms related to COVID‐19. No patients died within 30 days of receipt of NR. Median tacrolimus level pre‐ and post‐NR were 7.4 ng/ml (IQR, 6.6–8.6) and 5.2 (IQR, 3.6–8.7), respectively. Four patients experienced a supratherapeutic tacrolimus concentration after restarting tacrolimus post‐NR. Our results show the clinically significant interaction between NR and immunosuppressive agents can be reasonably managed with a standardized dosing protocol. Prescribers should carefully re‐introduce CNI after the NR course is complete.

11 January 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
NLNicholas W. Lange
Nicholas W. Lange
DSDavid M. Salerno
David M. Salerno
DJDouglas L. Jennings
Douglas L. Jennings
JCJason Choe
Jason Choe
JHJessica Hedvat
Jessica Hedvat
MPMarcus R. Pereira
Marcus R. Pereira

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
JHJessica Hedvat
Jessica Hedvat
NLNicholas W. Lange
Nicholas W. Lange
DSDavid M. Salerno
David M. Salerno
EDErsilia M. DeFilippis
Ersilia M. DeFilippis
DKDanielle Kovac
Danielle Kovac
MPMarcus R. Pereira
Marcus R. Pereira
Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ transplant recipients (SOTR) are not well described in the literature. The objective of this analysis was to characterize 30-day hospitalization and other key secondary endpoints experienced by outpatient SOTR with mild–moderate COVID-19 treated with nirmatrelvir/ritonavir (NR), sotrovimab, or no SARS-CoV-2 specific treatment. This IRB-approved, retrospective study included 154 SOTR with a documented positive SARS-CoV-2 infection between December 16, 2021 and January 19, 2022 (a predominant Omicron BA.1 period in New York City). Patients who received NR (N = 28) or sotrovimab (N = 51) experienced a lower rate of 30-day hospitalization or death as compared to those who received no specific treatment (N = 75) (p = .009). A total of three deaths occurred, all among patients who initially received no specific treatment prior to hospitalization. These results suggest a role for SARS-CoV-2 specific agents in the treatment of SOTR with COVID-19, and that there does not appear to be any difference in effectiveness when comparing NR versus sotrovimab.

1 October 2021 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
CBCraig J. Beavers
Craig J. Beavers
RDRobert J. DiDomenico
Robert J. DiDomenico
SDSteven P. Dunn
Steven P. Dunn
JCJenna Cox
Jenna Cox
LTLong To
Long To
DJDouglas L. Jennings
Douglas L. Jennings

1 August 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
DJDouglas L. Jennings
Douglas L. Jennings
NLNicholas Lange
Nicholas Lange
MSMichael Shullo
Michael Shullo
FLFarhana Latif
Farhana Latif
SRSusan Restaino
Susan Restaino
WBWilliam L. Baker
William L. Baker

7 July 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
SAShudhanshu Alishetti
Shudhanshu Alishetti
MFMaryjane Farr
Maryjane Farr
DJDouglas Jennings
Douglas Jennings
GSGeo Serban
Geo Serban
NUNir Uriel
Nir Uriel
MHMarlena V. Habal
Marlena V. Habal
HLA antibodies pose a significant barrier to transplantation and current strategies to reduce allosensitization are limited. We hypothesized that augmenting proteasome inhibitor (PI) based desensitization with costimulation blockade (belatacept) to mitigate germinal center (GC) responses might increase efficacy and prevent rebound. Four highly sensitized (calculated panel reactive antibody [cPRA] class I and/or II >99%, complement-dependent cytotoxicity panel reactive antibody [CDC PRA+], C1q+) heart transplant candidates were treated with the combination of belatacept and PI therapy, which significantly reduced both class I and II HLA antibodies and increased the likelihood of identifying an acceptable donor. Three negative CDC crossmatches were achieved against 3, 6, and 8 donor-specific antibodies (DSA), including those that were historically C1q+ binding. Posttransplant, sustained suppression of 3 of 3, 4 of 6, and 8 of 8 DSA (cases 1-3) was achieved. Analysis of peripheral blood mononuclear cells before and after desensitization in one case revealed a decrease in naïve and memory B cells and a reduction in T follicular helper cells with a phenotype suggesting recent GC activity (CD38, PD1, and ICOS). Furthermore, a shift in the natural killer cell phenotype was observed with features suggestive of activation. Our findings support synergism between PI based desensitization and belatacept facilitating transplantation with a negative CDC crossmatch against historically strong, C1q binding antibodies.